Norman D. Hanson
Norman Hanson joined Abelman Frayne & Schwab in 2011 as a partner. Prior to joining the firm, for 12 years Norman was a partner at Fulbright & Jaworski, a partner at Felfe & Lynch for 6 years and an associate for 8 years, and an associate at Cooper & Dunham for 2 years.
Norman’s practice focuses on patent prosecution, interferences, and counseling, in the areas of biotechnology, biochemistry, chemistry, and pharmaceuticals.
He has drafted over 400 patent applications, and has served as lead or associate counsel in approximately 15 interferences. His litigation experience includes deposition practice in the biotechnological and chemical arts, document review and preparation of pleadings. He has argued before the Court of Appeals for the Federal Circuit and was prevailing counsel in Bosies v. Benedict, 27 F. 3d 539 (1994), and In re Gangadharam, 889 F. 2d 1011 (1989).
- Secured a dominant patent on immunological treatment of cancer for a client which generated over 15 million dollars in licensing fees.
- Performed due diligence for a neutraceutical company leading to a multimillion dollar buy out.
- Represented two biotechnology clients as plaintiffs in infringement trials which led to very favorable settlements.
Bar and Court Admissions
- New York State Bar
- Federal Circuit Court of Appeals
- American Academy for the Advancement of Sciences
- American Bar Association
- New York State Bar Association
- Norman focuses his practice on biotechnology patent matters. Norman has been actively involved in all technical areas of biotechnology, including immunology, recombinant DNA, clinical diagnostics and new therapies. In addition, he has extensive experience involving cosmetic and pharmaceutical products, “nutraceuticals,” and diagnostic medicines and devices, as well as non-biotechnology based chemical and biological products and therapies.
- Columbia Law School, Juris Doctor, 1982
- Columbia College, Bachelor of Arts, 1979